Gemcitabine-Induced Reversible Posterior Leukoencephalopathy Syndrome: A Case Report and Review of the Literature-Reference-Cited by-同舟云学术

Gemcitabine-Induced Reversible Posterior Leukoencephalopathy Syndrome: A Case Report and Review of the Literature

Published:2007-11-01 Issue:11 Volume:12 Page:1332-1335
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Rajasekhar Anita¹,George Thomas J.¹

Affiliation:

1. Division of Hematology/Oncology, College of Medicine, University of Florida, Gainesville, Florida, USA

Abstract

Learning Objectives After completing this course, the reader will be able to: Describe the clinical and radiologic manifestations of RPLS.Define agents or inciting risk factors that have been implicated in the development of RPLS.Describe the treatment and outcome of RPLS, emphasizing supportive care and urgent discontinuation of the offending agent. Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.12-11-1332

Reference23 articles.

1. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial;Burris;J Clin Oncol,1997

2. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial;Brodowicz;Lung Cancer,2006

3. Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer;Delfino;Oncology,2004

4. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival;Albain;J Clin Oncol,2004

5. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG;Pfisterer;J Clin Oncol,2006

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of drug-induced posterior reversible encephalopathy syndrome using the food and drug administration adverse drug events reporting system database;Expert Opinion on Drug Safety;2024-03-13

2. Newly identified adverse events for gemcitabine using the Food and Drug Administration Adverse Event Reporting System;Expert Opinion on Drug Safety;2023-11-16

3. Posterior reversible encephalopathy syndrome in pregnancy: A case series of 5 cases;MGM Journal of Medical Sciences;2022

4. Delayed Gemcitabine-Induced Posterior Reversible Encephalopathy Syndrome;The American Journal of the Medical Sciences;2021-06

5. Neurological Aging and Cancer;Geriatric Oncology;2020